- Clinical stage biopharmaceutical company focused on rare respiratory diseases—Savara (SVRA) priced an underwritten public offering of ~23.81M shares at a price of $4.20 per share.
- Total gross proceeds of $130M are expected
- The underwriters have a 30-day option to purchase up
Savara prices $130M equity at $4.20 (SVRA:NASDAQ)
